SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Collage image of people arms gloves hold equipment hit hammer cut saw nail gun isolated on creative white background.
Executive appointments
Merck Reorganizes Human Health Work Into Two New Units
The new structure will help Merck as it slides toward a loss of exclusivity for Keytruda, pharma’s best-selling drug.
February 23, 2026
 · 
1 min read
 · 
Annalee Armstrong
Contemporary art collage. Businessmen, employees walking into open door symbolizing new opportunities. Way to success. Concept of business, promotion, motivation, ambitions and ideas
Government
Kennedy Ally Departs CDC Amid Leadership Shake-Up
Ralph Abraham, a vocal vaccine skeptic who served at the agency for just three months, has stepped down due to “unforeseen family obligations,” according to the CDC.
February 23, 2026
 · 
1 min read
 · 
Annalee Armstrong
Conceptual origami paper plane pulling business finance growth chart line flying upwards on blue sky background.
Approvals
Vanda Rebounds From Jet Lag Rejection With FDA Nod for Bipolar, Schizophrenia Drug
Bysanti is based on iloperidone, an active metabolite of a compound that forms the core of Fanapt, another drug by Vanda Pharmaceuticals.
February 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Collage halftone banner with two hands that put objects on scales. Halftone hands holding circle and square and put them on the scales. Concept of business balance in teamwork. Vector illustration.
Legal
REGENXBIO Secures Legal Win in Gene Therapy Patent Battle Vs. Sarepta
A lower court had previously ruled for Sarepta in the companies’ long-running dispute, finding that REGENXBIO’s AAV patent was invalid because its elements were naturally occurring. The appeals court on Friday said that this original decision adopts a “narrow” view of the invention.
February 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Hand collage holding dollar paper money isolated on yellow background. Using cash to buy concept. Halftone effect in pop art style illustration.
Mergers & acquisitions
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition
The centerpiece of the takeover is anito-cel, a CAR T therapy under development for relapsed or refractory multiple myeloma. An FDA decision on the therapy is expected by December 2026.
February 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Concept of saving money with a pink colored piggy bank held in a hand in front of a blackboard with hand drawn coins
Weight loss
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
Head-to-head trials are often reserved for approved therapies as drugmakers try to one-up each other to gain further market share. In this case, Novo Nordisk ran the test at the candidate stage, and the bet did not pay off.
February 23, 2026
 · 
4 min read
 · 
Annalee Armstrong
Insights
Historic ALS Investment Signals New Treatment Momentum
The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics’ first patient dosing in its TDP-43-targeting PIONEER-ALS trial and EverythingALS’ pharma consortia driving biomarker innovations and trial alignment.
February 23, 2026
 · 
3 min read
 · 
Jennifer C. Smith-Parker
Person isolating in solitude separated behind a wall concept for being different, shyness, self isolation or individuality
Sickle cell disease
Sickle Cell Gene Therapies Casgevy and Lyfgenia Still Lacking Traction 2 Years In
The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.
February 23, 2026
 · 
6 min read
 · 
Heather McKenzie
Human hands holding colorful pieces of puzzle. Vector hand drawn sketch illustration. Business team solving problem, joining and connecting jigsaw. Teamwork, partnership, business solution concept
MASH
Beyond Rezdiffra: The 4 Most Promising MASH Pipelines in Play
After last year’s ‘stampede’ for FGF21 assets, the focus for the metabolic dysfunction-associated steatohepatitis space has shifted toward differentiated approaches, such as THR-β agonists and combination treatments, that seek to mirror the commercial success of Madrigal’s Rezdiffra.
February 23, 2026
 · 
6 min read
 · 
Ben Hargreaves
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS